Lupin launches generic Sugammadex Injection in the US following FDA approval

The launch strengthens Lupin's injectable portfolio in the U.S. market and expands access to a generic alternative for the widely used perioperative medicine

Global pharmaceutical major Lupin Limited has launched its generic Sugammadex Injection in the United States after receiving approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA).

The company has introduced Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, which are bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC.

Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged two years and older undergoing surgery. 

The launch strengthens Lupin's injectable portfolio in the U.S. market and expands access to a generic alternative for the widely used perioperative medicine.